[{"name":"Optimizing the use of neratinib in the extended adjuvant setting (ID 797)","mode":"","is_cme":false,"info":{"presentation":"Optimizing the use of neratinib in the extended adjuvant setting <small>(ID 797)<\/small>","session":"Pierre-Fabre - Industry Satellite Symposium: How to do more to improve HER2-positive early breast cancer patient outcomes? <small>(ID 76)<\/small>","presenter":"Miguel Martin Jimenez<small> (Madrid, Spain)<\/small>","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/breast2020\/persons\/photos\/74.jpg"},"playlist":[{"name":"Optimizing the use of neratinib in the extended adjuvant setting","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/76\/v\/797_3c.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/breast2020\/76\/v\/797_3c.mp4","cover":"","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/76\/v\/797_3c.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/76\/v\/797_3c-thumbnails.vtt"}]}]{"provider":"CTI","provider_live":0,"type":1,"code":"8L240eK02Vk"}